follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
 product sale billion
 gaap loss per share
 non-gaap dilut ep per share
result oper third quarter end septemb financi result follow repres
year-over-year comparison third quarter third quarter total revenu billion
third quarter compar billion period net loss third quarter
billion per dilut share compar net incom billion per dilut share
period net loss third quarter includ up-front collabor licens
expens billion per share relat gilead global research develop collabor
agreement galapago nv galapago non-gaap net incom billion per dilut share
third quarter compar billion per dilut share period
royalti contract revenu
net incom loss attribut gilead
note non-gaap financi inform exclud acquisition-rel up-front collabor licens stock-bas
compens expens fair valu adjust equiti secur discret tax charg benefit
associ chang tax relat law guidelin reconcili non- financi
inform provid tabl page
total product sale third quarter billion compar billion period
third quarter product sale unit state europ locat billion
million million respect third quarter product sale unit state europ
locat billion million million respect
hiv product sale billion third quarter compar billion period
increas primarili driven higher sale volum result continu uptak biktarvi bictegravir
chronic hepat viru hcv product sale million third quarter compar
million period declin primarili due competit dynam
yescarta axicabtagen ciloleucel gener million sale third quarter compar
million period increas driven higher number therapi provid patient
continu expans europ
product sale includ product chronic hepat viru hbv cardiovascular oncolog
categori inclus vemlidi tenofovir alafenamid mg viread tenofovir disoproxil fumar mg
letairi ambrisentan mg mg ranexa ranolazin mg mg zydelig idelalisib mg
ambisom amphotericin liposom inject mg/vial cayston aztreonam inhal solut
mg/vial million third quarter compar million period
decreas primarili due expect declin ranexa letairi sale gener entri
research develop expens
sell gener administr expens sg
third quarter compar period
 expens increas primarili due up-front collabor licens expens
billion relat gilead global research develop collabor agreement galapago
furthermor expens non-gaap expens increas primarili due increas
invest gilead oncolog program hiv program research project
sg expens non-gaap sg expens increas primarili due higher promot expens
unit state expens associ expans gilead busi japan china
equival market debt secur
septemb gilead billion cash cash equival market debt secur
compar billion decemb third quarter gilead gener billion
oper cash flow paid billion connect global research develop collabor
agreement stock purchas agreement galapago repaid billion debt paid cash dividend
million util million stock repurchas billion paid galapago classifi cash
flow invest activ includ billion equiti invest
gilead revis full year guidanc initi provid februari revis juli
million except percentag per share amount
dilut ep impact acquisition-rel up-front collabor
licens stock-bas compens expens
corpor highlight includ announc
appoint andrew dickinson chief offic effect novemb
appoint merdad parsey chief medic offic effect novemb
launch radian initi meaning address new hiv infect death aids-rel
ill eastern europ central asia collabor elton john aid foundat
close global research develop collabor agreement galapago announc juli
collabor renown institut health innov renown collect analyz genet
electron health data enhanc understand nonalcohol steatohepat nash potenti
inform develop treatment option diseas
product pipelin updat includ announc
present week data phase finch finch trial filgotinib investig
oral select inhibitor treatment moderately-to-sever activ rheumatoid arthriti ra
consist support efficaci safeti toler profil demonstr week
analys present earlier year
submiss new drug applic filgotinib treatment adult ra japanes
ministri labor welfar mhlw
present data idweek confer includ
result discov trial evalu descovi emtricitabin mg/tenofovir alafenamid
mg hiv pre-exposur prophylaxi prep show signific improv key
measur bone renal safeti paramet subset studi particip switch
truvada prep emtricitabin mg/tenofovir disoproxil fumar mg descovi
releas latest data demonstr major metropolitan area unit state
highest use prep experienc greatest decreas new hiv diagnos
approv prep indic descovi food drug administr fda descovi
prep indic reduc risk sexual acquir infect adult adolesc weigh
least kg hiv-neg at-risk sexual acquir hiv exclud individu at-risk
european medicin agenc ema valid market author applic filgotinib
treatment adult ra applic evalu agenc
approv biktarvi china nation medic product administr treatment
infect adult without present past evid viral resist integras inhibitor class
emtricitabin tenofovir
plan bolster cell therapi manufactur capabl new viral vector facil
oceansid california new site build exist state-of-the-art manufactur capabl deliv
innov cell therapi peopl cancer includ yescarta investig t-cell receptor
inform present document prepar accord gener accept
account principl unless otherwis note non- manag believ non- inform
use investor consid conjunct gilead gaap financi inform manag
use inform intern oper budget financi plan purpos non-gaap inform
prepar comprehens set account rule use supplement
understand gilead oper result report non- measur may defin
calcul differ compani industri reconcili non-
financi inform provid tabl page
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
gilead research-bas biopharmaceut compani discov develop commerci innov medicin
area unmet medic need gilead product pipelin investig drug includ treatment
hiv/aid liver diseas seriou respiratori cardiovascular condit cancer inflamm market
product includ number categori first includ first complet treatment regimen hiv infect
avail once-daili singl pill first oral antiretrovir pill avail reduc risk acquir hiv
infect certain high-risk adult
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
global biopharmaceut compani develop deliv therapi patient
sever life-threaten diseas also ultra-rar alexion first commerci product soliri
eculizumab world first approv termin complement inhibitor today soliri approv nearli
countri treatment patient paroxysm nocturn hemoglobinuria pnh us european
union japan countri treatment patient atyp hemolyt urem syndrom ahu
discov develop manufactur deliv innov human therapeut use tool like advanc
human genet compani focus area high unmet medic need leverag biolog
manufactur expertis strive solut improv health outcom grown world
largest independ biotechnolog compani reach million patient around world develop
pipelin medicin breakaway potenti
biogen idec discov develop deliv patient world-wide innov therapi treatment
neurodegen diseas hemophilia autoimmun disord found world oldest
independ biotechnolog compani fortun compani billion annual revenu
biomarin found develop commerci innov biopharmaceut seriou diseas
medic condit compani four approv product naglazym galsulfas product wholli
develop commerci biomarin aldurazym laronidas develop joint ventur
genzym corpor kuvan sapropterin dihydrochlorid tablet develop partnership merck serono
divis merck kgaa darmstadt germani firdaps amifampridin approv
european commiss treatment lambert eaton myasthen syndrom
celgen global biopharmaceut compani discov develop commerci product treatment
cancer sever immun inflammatori condit clinic trial major medic
center use compound celgen
regeneron lead scienc technolog compani deliv life-transform medicin seriou diseas
found physician-scientist nearli year ago compani science-driven approach result four
fda-approv medicin numer product candid rang diseas includ ophthalmolog
rheumatoid arthriti atop dermat asthma pain cancer infecti diseas
seattl genet biotechnolog compani focus develop commerci innov empow
antibody-bas therapi treatment cancer industri leader antibody-drug conjug adc
technolog design har target abil monoclon antibodi deliv cell-kil agent directli
cancer cell adc intend spare non-target cell thu reduc mani toxic effect tradit
chemotherapi potenti enhanc antitumor activ addit one market product advanc
deep product pipelin address signific unmet medic need
seattl genet found headquart bothel washington suburb seattl
compani complet initi public offer march trade nasdaq stock market
symbol compani employe passion help peopl live cancer
shire part takeda
shire lead global biotechnolog compani focus serv peopl rare diseas highli
special condit strive develop best-in-class product mani avail
storag disord gastrointestin intern medicin endocrin hereditari angioedema grow
franchis oncolog
vertex global biotechnolog compani discov develop commerci innov new medicin
treat seriou diseas found cambridg vertex today research develop site
commerci offic us canada europ australia four year row scienc magazin name
vertex one top employ life scienc
genet engin ge seed varieti commerci introduc adopt rate crop
increas rapidli year follow current percent corn upland cotton soybean canola
sugarbeet produc use ge varieti
ht crop toler potent herbicid glyphos glufosin dicamba potenti
damag non-g crop insect-resist bt crop contain gene soil bacterium bacillu thuringiensi
produc insecticid protein although ge trait develop viru fungu resist
drought resist enhanc protein oil vitamin content ht bt trait commonli use
 crop product ht seed also wide use alfalfa canola sugar beet product ge
acr plant three major field crop corn cotton soybean
though ge seed tend expens convent one plant tend increas crop yield
lower pesticid cost and/or provid time labor save impact ge crop vari crop year
locat bt crop tend higher yield non-bt crop insect present insecticid cost also tend
lower field bt crop plant plant ht crop tend simplifi weed manag decis
lead time labor save ht adopt also tend promot use conserv tillag
technolog often induc farmer substitut herbicid glyphos toxic herbicid howev
larg increas glyphos use recent led develop glyphosate-resist weed popul
spread resist weed popul potenti erod benefit associ ht product
er conduct research number agricultur biotechnolog issu includ
extent adopt commerci avail varieti ge crop farmer data extent
ge adopt corn soybean cotton adopt genet engin alfalfa canola
sugarbeet unit state novemb inform
farmer motiv adopt ge crop relationship adopt ge crop yield
relationship adopt ge crop pesticid use genet engin crop
unit state februari first decad genet engin crop unit
state april econom glyphos resist manag corn
soybean product april inform issu
econom effect adopt ge crop off- incom technolog adopt
econom perform februari topic
research develop seed industri chapter research invest market
structur food process agricultur input biofuel industri world-wide decemb
genet engin crop unit state februari
consum attitud toward biotechnolog role consum prefer shape market trend
genet engin crop unit state februari first decad
genet engin crop unit state april inform
er also initi research coexist ge organic/non-g crop product
econom issu coexist organ genet engin ge non-g crop
februari inform
agricultur environment indic
agricultur product affect wide rang natur resourc includ land water air report provid
concis inform natur resourc land water commerci input energi nutrient
pesticid antibiot technolog use agricultur sector contribut
environment qualiti assist public privat decis make around best manag resourc
impact report explor complex link among public polici econom condit farm
conserv practic product technolog chang resourc use environ object
provid comprehens sourc data analysi factor affect resourc use qualiti american
studi find
notabl find product includ
small farm famili farm less revenu made percent farm
percent farm least revenu account percent product
almost percent billion acr land unit state use agricultur purpos
includ crop graze pastur rang forest farmstead farm road
earli averag farm real estat valu nearli doubl inflation-adjust term
sinc valu cropland declin nearli percent
percent land farm owner-oper remain land rent landown
tenant farm oper non-oper landlord percent rent farmland
agricultur output grew percent per year aggreg input use increas
percent annual averag
sinc earli private-sector food agricultur research develop grown much
rapidli public-sector privat sector spent nearli three time much public sector
corn cotton soybean grower wide adopt genet engin ge herbicide-toler ht
insect-resist bt seed sinc percent corn cotton soybean acr plant unit
state use ht seed percent corn cotton acr use seed also contain bt trait
herbicid applic rate per plant acr compar percent corn percent
cotton percent wheat percent soybean type herbicid use chang time
commerci fertil consumpt million short ton corn winter wheat cotton
nitrogen recoveri rate hover around percent phosphat recoveri rate percent
irrig farm repres percent farm account percent farm
sale acreag water-effici sprinkler drip/trickl system rose
percent irrig area western unit state
precis agricultur compris technolog guidanc system variable-r technolog vrt
percent plant corn soybean rice acreag farm use vrt
end percent broiler chicken rais without antibiot
share finish hog oper report know report whether antibiot
use growth promot rose percent percent
conserv tillag reduc soil eros sediment loss use around percent soybean
acr percent cotton percent corn percent wheat
 organ retail sale reach estim billion number certifi organ oper
unit state doubl
anim manur provid sourc nutrient crop around percent broiler oper
nutrient manag plan compar percent hog oper percent dairi
across nation percent assess river stream percent lake percent
bay estuari nation impair water qualiti agricultur largest sourc impair river
stream second-largest sourc lake pond
drought lead caus product risk crop insur indemn payment unit state
practic irrig adopt reduc drought vulner
mani farmer rancher use practic enhanc soil health percent cropland acr
no-til percent plant cover crop two practic promot soil health
base land use-bas measur qualiti pollin forag habitat increas
declin declin greatest northern plain summer ground commerci beehiv
number farm produc energi electr onfarm solar panel geotherm
exchang wind turbin small hydro methan digest increas percent
feder fund five largest voluntari program encourag land retir adopt conserv
practic work land roughli billion real inflation-adjust term conserv spend
increas declin act
sinc freshwat wetland contigu unit state held steadi around million acr
acreag enrol usda conserv reserv program crp declin
million million acr howev land enrol continu portion crp increas million
estim percent farm enrol usda environment qualiti incent program
eqip percent enrol conserv stewardship program csp
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
